Novartis has a third FDA-approved indication ... For comparison, PNH and IgAN affect around 10-20 and 25 people per million, respectively. The approval follows positive results for Fabhalta ...

Apellis reported a net loss of $92.2 million for the first quarter of 2025 compared to a net loss of $66.4 million for the same period in 2024. Cash. As of March 31, 2025, Apellis had $358.4 million ...

Generated $166.8 million in 1Q 2025 revenues, including $149.9 million in U.S. net product salesSYFOVRE® (pegcetacoplan injection) injection demand grew 4% quarter-over-quarter, with U.S. net product ...

The survey was conducted from March 10 through April 9, when the Department of Government Efficiency was in news ...

Novartis has claimed accelerated approval from the FDA for Vanrafia ... which also include paroxysmal nocturnal haemoglobinuria (PNH) and C3 glomerulopathy (C3G). The company acquired rights ...

The FDA has approved a dihydroergotamine-based nasal powder for the acute treatment of migraine with or without aura in ...

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson’s IMAAVY (nipocalimab-aahu), a human FcRn-blocking ...

The U.S. Food and Drug Administration has approved Edwards Lifesciences' SAPIEN 3 platform, a transcatheter aortic valve ...